2001
Nicotine Receptor Inactivation Decreases Sensitivity to Cocaine
Zachariou V, Caldarone B, Weathers-Lowin A, George T, Elsworth J, Roth R, Changeux J, Picciotto M. Nicotine Receptor Inactivation Decreases Sensitivity to Cocaine. Neuropsychopharmacology 2001, 24: 576-589. PMID: 11282258, DOI: 10.1016/s0893-133x(00)00224-4.Peer-Reviewed Original ResearchConceptsPlace preferenceDA turnoverLow doseHigh-affinity nicotinic acetylcholine receptorsMesolimbic DA systemHigh-affinity nAChRsNicotinic antagonist mecamylamineWild-type miceMesolimbic dopamine systemFos-related antigensProperties of nicotineCocaine place preferenceΒ2 subunitNicotinic acetylcholine receptorsAntagonist mecamylamineDA releaseMetabolite DOPACNeurochemical changesSubthreshold doseType miceDopamine systemPsychomotor stimulantsAcetylcholine receptorsHigh dosesBrain regions
1991
D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey.
Elsworth J, Lawrence M, Roth R, Taylor J, Mailman R, Nichols D, Lewis M, Redmond D. D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. Journal Of Pharmacology And Experimental Therapeutics 1991, 259: 595-600. PMID: 1682479.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzamidesBenzazepinesBlinkingChlorocebus aethiopsDopamine AgentsDopamine AntagonistsDose-Response Relationship, DrugMaleOxazinesPhenanthridinesReceptors, DopamineRemoxiprideTime FactorsConceptsD2 dopamine receptorsDopamine receptorsSpontaneous blink rateBlink ratePrior administrationSCH 23390D1 agonistPartial D1 agonistSpecific D1 antagonistSpecific D2 antagonistRole of D1Dose-dependent increaseSpontaneous eye blink rateFull D1 agonistSpecific D2 agonistReceptor-selective drugsAfrican green monkeysEye blink rateDopamine agonistsSKF 38393D2 agonistD1 antagonistD2 antagonistReceptor subtypesD2 receptors
1982
Clonidine suppression of noradrenergic hyperactivity during morphine withdrawal by clonidine: biochemical studies in rodents and primates.
Roth R, Elsworth J, Redmond D. Clonidine suppression of noradrenergic hyperactivity during morphine withdrawal by clonidine: biochemical studies in rodents and primates. The Journal Of Clinical Psychiatry 1982, 43: 42-6. PMID: 6806253.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBrainClonidineDose-Response Relationship, DrugHaplorhiniHumansMethoxyhydroxyphenylglycolMorphine DependenceNaloxoneNeuronsNorepinephrineRatsSubstance Withdrawal SyndromeConceptsBrain levelsMHPG accumulationNE turnoverNE neuronsLocus coeruleusNaloxone-insensitive mechanismAdministration of naloxoneMorphine-dependent animalsNE systemDose-dependent degreeNon-human primatesNE metabolismMorphine withdrawalOpiate withdrawalClonidine suppressionImpulse flowNoradrenergic hyperactivityClinical studiesCSF measuresControl monkeysClonidineElectrophysiological studiesMHPGBiochemical measuresPilot data
1977
DEPRENYL IN PARKINSON'S DISEASE
Lees A, Kohout L, Shaw K, Stern G, Elsworth J, Sandler M, Youdim M. DEPRENYL IN PARKINSON'S DISEASE. The Lancet 1977, 310: 791-795. PMID: 71602, DOI: 10.1016/s0140-6736(77)90725-5.Peer-Reviewed Original ResearchConceptsParkinson's diseaseDouble-blind crossover trialDoses of levodopaEarly morning akinesiaPeripheral decarboxylase inhibitorLevodopa-induced dyskinesiaTotal daily dosesMajority of patientsIdiopathic Parkinson's diseaseDose akinesiaUntreated patientsCrossover trialDosage reductionDaily dosesDecarboxylase inhibitorTherapeutic effectCheese effectLarge dosesPatientsLevodopaAlternate daysAkinesiaDeprenylDiseaseB inhibitor